# A Single Arm Study Evaluating the Efficacy, Safety and Tolerability of Ofatumumab in Patients With Relapsing Multiple Sclerosis

> **NCT04486716** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 111 (actual)

## Conditions studied

- Relapsing Multiple Sclerosis

## Interventions

- **DRUG:** Ofatumumab

## Key facts

- **NCT ID:** NCT04486716
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-19
- **Primary completion:** 2023-11-20
- **Final completion:** 2024-10-21
- **Target enrollment:** 111 (ACTUAL)
- **Last updated:** 2026-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04486716

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04486716, "A Single Arm Study Evaluating the Efficacy, Safety and Tolerability of Ofatumumab in Patients With Relapsing Multiple Sclerosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04486716. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*